LumiraDx plans to begin commercialisation of the new assay in the US and UK. Credit: Renate Köppel / Pixabay.

LumiraDx has secured US Food and Drug Administration (FDA) Emergency Use Authorization as well as UK Health Security Agency (UKHSA) validation for a multiplex test for Covid-19 and influenza A and B.

The multiplex Covid and influenza molecular test, named LumiraDx SARS-CoV-2 & Flu A/B STAR Complete assay, allows laboratories to quickly identify and differentiate individuals with respiratory viral infections consistent with Covid-19.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Clinical signs and symptoms of influenza and SARS-CoV-2 respiratory virus infections can be identical, making correct identification essential for treating patients, LumiraDx said.

The multiplex test allows for the concurrent detection and differentiation of influenza A, influenza B and SARS-CoV-2 infections within a period of 20 minutes or less.

Furthermore, it makes use of qSTAR technology, which allows direct amplification and high throughput on open molecular platforms to provide highly sensitive results.

LumiraDx Molecular Diagnostics Business president Sanjay Malkani said: “With the limited number of direct amplification multi-analyte tests available, we believe that this test will become a fundamental tool for the detection and differentiation of SARS-CoV-2 from influenza.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As the burden of respiratory illness continues, we look forward to providing our clinical diagnostic lab and reference lab customers with a high-throughput, highly sensitive multiplex test with results available in 20 minutes – and the added benefit of accurately detecting influenza and Covid from a single sample.”

LumiraDx plans to begin commercialisation of the LumiraDx SARS-CoV-2 & Flu A/B STAR Complete assay in the US and UK.

It was initially launched in the European Union and other markets that accept the CE-IVD marking last June.